Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc has demonstrated a strong foundation for growth through its completion of the CLARITY program, which includes three Phase 3 trials showing impressive efficacy and safety, positioning the company for a leading market profile in the treatment of presbyopia. The company's financial forecasts indicate a path to profitability in 2028, suggesting sustainable financial health in the coming years. Additionally, LENZ plans to enhance its sales force, reflecting confidence in market demand and potential revenue growth as it nears commercialization of its ophthalmic therapies.

Bears say

LENZ Therapeutics faces significant commercial challenges in changing consumer behavior related to presbyopia, which may hinder the adoption and success of its therapies. Moreover, the company has a limited product pipeline, lacking diversification beyond its primary offering, Vizz, which could restrict future growth opportunities. Additionally, competitive pressures from other presbyopia treatments and potential generic challenges to Vizz's intellectual property introduce further risks that threaten the company's market position and financial performance.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.